European Journal of Dermatology
MENULichen planus in psoriatic patients treated with interleukin 17 inhibitors: two additional cases and a literature review Volume 32, issue 6, November-December 2022
Figures
1 Department of Dermatology, CHU Carémeau, 30029 Nimes, France
2 Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, 34298 Montpellier, France
- DOI : 10.1684/ejd.2022.4360
- Page(s) : 795-6
- Published in: 2022
Lichen planus (LP)-like eruptions have been reported in patients under anti-tumour necrosis factor-α (TNF-α) treatment [1]. Recently, interleukin 17 (IL-17) inhibitor treatment has also been linked to the induction of LP and lichenoid eruptions [2–6]. Here, we report two additional cases of oral and mucocutaneous LP after secukinumab therapy for psoriasis and briefly review the referenced literature on this phenomenon.Case 1 was a 63-year-old male patient who began secukinumab for treatment of severe [...]